Incyte announces new 54-week data on safety, efficacy of povorcitinib

Incyte (INCY) announced 54-week data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients with moderate to severe hidradenitis suppurativa, HS. The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology, AAD, Annual Meeting, being held March 27-31, 2026, in Denver. “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical benefit with a manageable safety profile, underscoring its promise to help transform the HS treatment landscape as the first oral option. We look forward to advancing our regulatory applications in the U.S. and Europe.”